Effects of radiofrequency radiation in the presence of gold nanoparticles for the treatment of renal cell carcinoma.
Abstract
The most common type of kidney cancer is renal cell carcinoma (RCC), which accounts for more than 80% of all kidney cancers. The aim of this study was to evaluate the effects of radiofrequency (RF) radiation in the presence of gold nanoparticles (GNPs) for the treatment of RCC. Human embryonic kidney (HEK) cancer cells were divided into 6 groups. Various tests were performed on HEK cells in the presence of RF and GNPs. In order to investigate the radiation effects on the cells' survival, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-iphenyltetrazolium bromide] assay was performed at different days during and post-irradiation period. The repeated measure analysis of variance (ANOVA) method was used for statistical analysis of the cells' survival using SPSS version 16.0. A significant level of 0.05 was considered to the tests. Using the ANOVA test, a significant decrease in cell's survival was seen in the RF exposed group 3 compared to the control group (=0.035). While, differences were not significant between RF exposed group 2 and the control group (>0.05). A significant decrease in cell's survival in the RF exposed groups 5 (=0.025) and 6 (=0.018) at the presence of GNP compared to the control group was seen. Results of this study showed that, this method can be efficiently used for RCC treatment as an alternative to nephrectomy. More follow up in vivo studies on mammalians are needed to investigate the potential of the presented method for clinical applications.
AI evidence extraction
Main findings
HEK cancer cells were divided into 6 groups and assessed for survival using MTT during and after RF irradiation, with and without gold nanoparticles (GNPs). A significant decrease in cell survival was reported for one RF-exposed group (group 3) versus control (p=0.035), while another RF-exposed group (group 2) did not differ significantly from control (p>0.05). In the presence of GNPs, significant decreases in survival were reported for RF-exposed groups 5 (p=0.025) and 6 (p=0.018) versus control.
Outcomes measured
- Cell survival (MTT assay)
Limitations
- In vitro study (cell culture) with no in vivo/clinical outcomes
- RF exposure parameters (e.g., frequency, SAR, duration) not reported in the abstract
- Sample size and detailed group definitions not provided in the abstract
- Authors note need for follow-up in vivo mammalian studies
View raw extracted JSON
{
"study_type": "in_vitro",
"exposure": {
"band": "RF",
"source": null,
"frequency_mhz": null,
"sar_wkg": null,
"duration": null
},
"population": "Human embryonic kidney (HEK) cancer cells (renal cell carcinoma model)",
"sample_size": null,
"outcomes": [
"Cell survival (MTT assay)"
],
"main_findings": "HEK cancer cells were divided into 6 groups and assessed for survival using MTT during and after RF irradiation, with and without gold nanoparticles (GNPs). A significant decrease in cell survival was reported for one RF-exposed group (group 3) versus control (p=0.035), while another RF-exposed group (group 2) did not differ significantly from control (p>0.05). In the presence of GNPs, significant decreases in survival were reported for RF-exposed groups 5 (p=0.025) and 6 (p=0.018) versus control.",
"effect_direction": "mixed",
"limitations": [
"In vitro study (cell culture) with no in vivo/clinical outcomes",
"RF exposure parameters (e.g., frequency, SAR, duration) not reported in the abstract",
"Sample size and detailed group definitions not provided in the abstract",
"Authors note need for follow-up in vivo mammalian studies"
],
"evidence_strength": "very_low",
"confidence": 0.7399999999999999911182158029987476766109466552734375,
"peer_reviewed_likely": "yes",
"keywords": [
"radiofrequency",
"RF radiation",
"gold nanoparticles",
"GNP",
"renal cell carcinoma",
"RCC",
"human embryonic kidney cells",
"HEK",
"MTT assay",
"cell survival",
"in vitro"
],
"suggested_hubs": []
}
AI can be wrong. Always verify against the paper.
Comments
Log in to comment.
No comments yet.